#United States #New York #Class Action #Pomerantz Law #Nutex Health

Class Action Lawsuit Filed Against Nutex Health Inc.

Overview
On September 3, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against Nutex Health Inc., identified by its ticker symbol NUTX on NASDAQ, along with several of its officers. The lawsuit aims to represent all individuals and entities who acquired Nutex securities between August 8, 2024, and August 14, 2025. This class action seeks to recover damages for violations of federal securities laws, particularly focusing on sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

Details of the Class Action

The case has been filed in the United States District Court for the Southern District of Texas, and is officially recorded under docket number 25-cv-03999. Investors who purchased Nutex stock within the defined Class Period have until October 21, 2025, to request the Court's appointment as Lead Plaintiff.

In a bid to provide up-to-date information, investors may download a copy of the Complaint from Pomerantz’s official website. Any inquiries regarding this action can be directed to Danielle Peyton at Pomerantz LLP's contact number.

Understanding Nutex Health Inc.

Nutex, a physician-led healthcare services company, began its public trading journey in April 2022 via a reverse merger. The organization operates through three main divisions: a hospital segment consisting of 24 facilities spread across 11 states, a population health management division, and a real estate sector. Notably, Nutex primarily functions as an out-of-network provider, generating a significant portion of its revenue from third-party payors, including commercial insurance and Medicare.

Historically, out-of-network healthcare provisions have led to patients being billed at rates higher than those stipulated by their health plans, often subjecting them to unexpected 'surprise bills.' To mitigate these practices, Congress enacted the No Surprises Act (NSA) effective January 1, 2022, mandating private health plans to cover out-of-network claims and ensuring that patients are not charged more than in-network cost-sharing amounts for surprise medical bills.

Challenges Facing Nutex Post-NSA

Since the NSA's enforcement, Nutex has encountered significant challenges. The legislation allows for a median cost-sharing calculation based on the in-network rates paid by health plans. Consequently, Nutex’s ability to charge elevated prices on out-of-network services has diminished. Notably, Nutex reported a decline in average payments from insurers for patient claims, specifically citing a drop of nearly 30% since the NSA's initiation. The company has further emphasized the necessity of appeals through the Independent Dispute Resolution (IDR) process to recover reasonable payments.

In July 2024, Nutex sought assistance from HaloMD, a third-party IDR vendor, to enhance recovery from out-of-network claims. This partnership was initially undisclosed to investors, yet Nutex later capitalized on the success of its arbitration strategy, asserting significant revenue gains derived from arbitration.

Accusations Against Nutex and HaloMD

Despite claims of successful revenue recovery attributed to arbitration, serious allegations have arisen. Health advocacy firm Blue Orca Capital published a report on July 22, 2025, asserting that HaloMD engaged in deceptive practices to secure inflated payments for Nutex by flooding the arbitration system with ineligible claims. The report labeled these schemes as potentially fraudulent, further indicating that legal actions against HaloMD by insurance companies could precipitate a reconsideration of financial strategies for Nutex.

Following the report's publication, Nutex's stock price fell by over 10% in a single day. The company attempted to address concerns through a press release on July 24, disputing the claims made by Blue Orca and expressing intentions to provide updates in their upcoming financial disclosures. However, subsequent challenges persisted when Nutex announced delays in filing its Form 10-Q, revealing critical adjustments concerning stock-based compensation for ongoing projects.

Conclusion

Pomerantz LLP stands recognized as a leading firm in corporate and securities class action litigation with a robust reputation for representing victims of corporate misconduct. Investors are encouraged to stay alert for further updates regarding the class action against Nutex Health Inc. as the situation continues to evolve. Legal representatives remain committed to the pursuit of justice for investors affected by the alleged misconduct associated with Nutex and its operations in the healthcare space.